The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Rates of central nervous system (CNS) metastases in patients with advanced non-small cell lung cancer (NSCLC) and somatic EGFR mutations initially treated with gefitinib or erlotinib versus chemotherapy.
S. Heon
No relevant relationships to disclose
B. Y. Yeap
No relevant relationships to disclose
N. I. Lindeman
No relevant relationships to disclose
M. S. Rabin
Consultant or Advisory Role - Genentech
D. M. Jackman
Consultant or Advisory Role - Foundation Medicine
B. E. Johnson
Consultant or Advisory Role - AstraZeneca (U); Boehringer Ingelheim (U); Genentech (U); KEW Group (U); Millennium (U); Pfizer (U)
Stock Ownership - Celgene
Other Remuneration - Genzyme